The AI/ML-based software demonstrates a high level of performance in a multicenter validation cohort enriched for cancer prevalence, cancer stage, and small non-spiculated cancer nodules, with high sensitivity across nodule size and cancer stage. This AI/ML-based software demonstrated its potential to optimize the detection, localization, characterization and management of small screen-detected nodules leading to earlier diagnosis, more effective therapy, impacting survival of cancer patients.

Poster presented at the American Thoracic Society Congress in San Francisco